Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations characterized by the development of pathogenic autoantibodies manifesting in inflammation of target organs such as the kidneys, skin and joints. Genome-wide association studies have identified genetic variants in the UBE2L3 region that are associated with SLE in subjects of European and Asian ancestry. UBE2L3 encodes an ubiquitin-conjugating enzyme, UBCH7, involved in cell proliferation and immune function. In this study, we sought to further characterize the genetic association in the region of UBE2L3 and use molecular methods to determine the functional effect of the risk haplotype. We identified significant associations between variants in the region of UBE2L3 and SLE in individuals of European and Asian ancestry that exceeded a Bonferroni-corrected threshold (Po1Â10
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by self-reactive antibodies that form immune complexes leading to systemic inflammation and organ failure. SLE susceptibility is strongly influenced by both genetic and environmental factors. Recent candidate gene and genomewide association studies have identified more than 30 susceptibility loci for SLE. 1 --8 Single-nucleotide polymorphisms (SNPs) in the region of UBE2L3, which encodes the ubiquitin-conjugating enzyme, UBCH7, demonstrate association with SLE in multiple independent SLE cohorts of European and African-American ancestry, 9, 10 and correlate most significantly with patients developing anti-double-stranded DNA antibodies. 11 Variants in the region of UBE2L3 have also been reported to be associated with several other autoimmune disorders such as Crohn's disease, 12, 13 celiac disease 14 and rheumatoid arthritis. 9, 14 Gene expression studies suggest that variants in the vicinity of UBE2L3 regulate UBE2L3 expression, thus providing a potential mechanism by which UBE2L3 influences susceptibility to autoimmune diseases.
Post-translational ubiquitination of proteins is an important process in eukaryotes that is responsible for the degradation of short-lived and abnormal cytosolic proteins and the regulation of cellular signaling pathways. 15 Three classes of enzymes, ubiquitinactivating enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) constitute the system by which ubiquitin is transferred to target proteins. UBE2L3, located at chromosome 22q11.2, is a member of the E2 ubiquitin-conjugating enzyme family and has been demonstrated to participate in the ubiquitination of p53, 16 c-Fos and the nuclear factor-kB (NF-kB) precursor p105 in vitro. 17, 18 Recent studies have further revealed that UBE2L3 is involved in cell proliferation. 19 To more thoroughly evaluate the UBE2L3 locus in SLE, we fine mapped and imputed SNPs in five diverse ethnic populations using a custom genotyping array, publicly available data sets of human variation and a targeted resequencing data set enriched for subjects with SLE risk haplotypes. We identified a single 67 kb risk haplotype associated with SLE and characterized the effect of the risk haplotype on gene expression by using quantitative PCR and western blotting. Our data demonstrate that both UBE2L3 mRNA transcripts and UBCH7 protein expression is increased by variants carried on the SLE risk haplotype, suggesting a mechanism by which variants in the region of UBE2L3 influence the pathogenesis of SLE.
RESULTS
Genome-wide association studies have identified genetic association with variants in the vicinity of UBE2L3 and multiple autoimmune diseases. In an effort to identify the causal variants responsible for association with SLE, we genotyped 57 SNPs in and around UBE2L3 along with 347 ancestry-informative markers (AIMs) in 8922 independent SLE cases and 8077 independent controls across five ethnic populations (Table 1, Supplementary  Figure 1 and Supplementary Tables 1 --3) . After applying a series of quality control (QC) filters, 55 genotyped SNPs and 262 AIMs were available for further analyses. To enrich our data set for additional untyped SNPs, we imputed a minimum of 285 SNPs from the 1000 Genomes Project. Single-marker logistic regression analyses, adjusting for gender and global ancestry estimates, revealed significant associations between multiple SNPs and SLE surpassing a Bonferroni-corrected threshold (Po1Â10 À4 ). In individuals of European ancestry, the strongest signal was observed at rs131658 (P ¼ 6.50Â10
À7
, odds ratio (OR) ¼ 1.24, 95% confidence interval (CI) ¼ 1.14 --1.35; Figure 1a ). In the Asian population, the strongest signal occurred at rs5754177 (P ¼ 1.98Â10 À6 , OR ¼ 1.33, 95% CI ¼ 1.18 --1.50; Figure 1b ). We also observed weaker evidence of association not exceeding the Bonferroni-corrected threshold in other populations with the optimal signals at rs11089629 for African Americans (P ¼
1.23Â10
À3 , OR ¼ 1.18, 95% CI ¼ 1.07 --1.30; Figure 1c ), rs390408 for Hispanics (P ¼ 2.89Â10 À3 , OR¼ 1.23, 95% CI ¼ 1.07 --1.42; Figure 1d ) and rs11705317 for Gullah (P ¼ 1.74 Â 10 À2 , OR ¼ 0.27, 95% CI ¼ 0.09 --0.79; Figure 1e ). When all populations were combined in meta-analysis, rs7444 produced the most significant association (P combined ¼ 2.21 Â 10 À14 ; Supplementary 
À7
) spanning the UBE2L3 region (haplotype H2; Figure 2 ). Similarly, a single risk haplotype harboring the majority of alleles in the EA risk haplotype was also present in Asian (haplotype H2; Supplementary Figure 2A Figure 2C ). Strong linkage disequilibrium was observed on the risk haplotype in all four populations and limited the utility of trans-population mapping or conditional analysis to further isolate a minimal risk segment. These results suggest that a single risk effect common to these populations may be responsible for the association with SLE.
Previous studies have demonstrated that variants in the region of UBE2L3 influence UBE2L3 transcript expression; 13 therefore, we evaluated whether the SLE-associated risk haplotype produced a similar molecular phenotype. To evaluate UBE2L3 mRNA and UBCH7 protein expression, quantitative real time PCR and western blotting was performed in an independent set of Epstein --Barr virustransformed B-cell lines under resting conditions. Cell lines were selected based on whether they contained 0, 1 or 2 copies of the UBE2L3 risk haplotype as defined by the rs7444-C risk allele. Concordant with other published studies, we observed increased UBE2L3 mRNA expression and increased expression of UBCH7 protein as a function of the number of copies of the risk haplotype (P ¼ 0.0004 and 0.0068, respectively (one-way analysis of variance); Figures 3a and b and Supplementary Figure 3 ). 
DISCUSSION
In this study, we observed significant associations between variants in UBE2L3 and SLE in individuals of European, Asian and African-American ancestry. Weaker association evidence was also observed in the Hispanic and Gullah populations due in part to the smaller samples sizes of these two groups (Table 1) . Risk variants were carried on a 67 kb risk haplotype tagged by the proxy SNP rs7444, in all populations demonstrating association with SLE. As the variants in this haplotype block were highly correlated across the different populations, we were unable to further narrow this SLE-associated DNA segment using conditional analyses or transpopulation mapping.
In line with data published in Crohn's disease, we observed higher levels of UBE2L3 mRNA and UBCH7 protein expression in EBV cell lines carrying the risk haplotype. This suggests that similar molecular mechanisms in UBE2L3 that influence susceptibility to autoimmunity are shared between SLE and CD. The precise mechanism by which causal variants on the UBE2L3 risk haplotype influence the expression of UBE2L3 is not yet defined, but we hypothesize that this could be due to the modification of mRNA stability and/or modification of the binding affinity of transcription factors to the UBE2L3 promoter. Further studies geared toward identification of the causal variant(s), which underlies the effect on gene and protein expression are required.
Ubiquitination is a critical post-translational protein modification for regulation of NF-kB signaling; 20 however, little is known about how UBCH7 mediated ubiquitination might impact NF-kB signaling. In a cell free system, Orian et al. 18 demonstrated that the NF-kB precursor protein, p105, was a substrate for UBCH7-mediated ubiquitination. At rest, p105, encoded by the gene, NF-kB1, undergoes constitutive proteosomal processing to yield the NF-kB subunit, p50. Unprocessed p105 functions as an inhibitor of NF-kB by retaining p50 homodimers in the cytoplasm using ankyrin repeats located in the C-terminal portion of the protein. 21 Following cellular activation, p105 is phosphorylated and undergoes complete proteosomal degradation, allowing bound p50 homodimers to translocate to the nucleus. It is possible that UBCH7-mediated ubiquitination of p105 may ). The orange solid line denotes the recombination rate calculated from the combined HapMap CEU, YRI and CHB þ JPT data. Adjusted for sex and global ancestry estimates.
The association of UBE2L3 with SLE S Wang et al result in increased proteosomal processing and/or degradation of p105, resulting in increased levels of free p50 homodimers. UBCH7 has been demonstrated to function with the HECT (homologous to the E6-associated protein carboxy terminus) family E3 ubiquitin ligase, ITCH, in in vitro ubiquitination assays. 22, 23 ITCH participates in the regulation of NF-kB along with RNF11, TAX1BP1 and A20 as part of a protein complex known at the ubiquitin-editing complex. 24 Recent data demonstrate that UBCH7 is restricted to HECT and RBR (RING-in-between-RING) type E3 ligases that underscores the possibility that UBCH7 and ITCH could function together to ubiquitinate substrate proteins; however, to our knowledge, a physical interaction between ITCH and UBCH7 has not yet been demonstrated in vivo.
In summary, our data support a role for variants in the UBE2L3 locus in the predisposition to SLE in multiple ethnic populations. The UBE2L3 locus demonstrates low haplotype diversity with a single risk haplotype associated with SLE. This risk haplotype carries causal variants that result in increased expression of UBE2L3 transcripts and UBCH7 protein. Future work will now focus on the isolation and characterization of the variants that result in this expression phenotype and on the role of UBCH7 function in immune cell signaling.
MATERIALS AND METHODS Subjects
In this study, the following independent case and control subjects were collected, respectively: African-American (1569/1893), Asian (1328/1348), European-ancestry (4248/3818), African-American Gullah (155/131) and Hispanic enriched for the Amerindian --European admixture (1622/887) populations (Supplementary Table 1 ). SLE cases were determined by meeting at least four of the eleven 1997 ACR revised criteria for SLE. Case and control samples were obtained from multiple sites with the Institutional Review Board approval from each institution and processed at the Oklahoma Medical Research Foundation (OMRF) under the OMRF Institutional Review Board.
Genotyping and QC
The Illumina iSelect platform at OMRF was employed to genotype 57 SNPs and 347 genome-wide AIMs. 25, 26 SNP QC measures included well-defined cluster scatter plots, a call rate 490%, a minor allele frequency 40.001 and Hardy --Weinberg proportion test P-value in controls 40.001 for inclusion. For the AIMs, we removed AIMs with low call rates (o90%), low minor allele frequencies (o0.001) and that are in LD with each other (r 2 40.2). We did not perform the Hardy --Weinberg proportion test for the AIM QC to avoid AIMs being inadvertently dropped due to monomorphic states in one of the ethnic groups. Principal components 27 calculated using R and global ancestry estimated using ADMIXMAP 28, 29 (with ancestral allele frequencies from African, European, American, Indian and East Asian population) were utilized to pinpoint population outliers (Supplementary Figure 1) and to adjust the logistic regression models for controlling population structure in our association analyses. A total of 1135 samples were removed because they were duplicates (the proportion of alleles shared identity by descent 40.4), sample heterozygosity outliers (45 standard deviation from the mean), population outliers, low call rate (o90%) or gender discrepancies between reported gender Figure 2 . Analyses of 34 associated SNPs present on UBE2L3 region in European-ancestry population. Top: UBE2L3 haplotype association analysis with haplotype frequencies 45%. Alleles in white boxes represent the major alleles and those in gray boxes represent the minor allele for each haplotype. Bottom: the plot of the pairwise linkage disequilibrium (LD) of 34 associated SNPs with the intensity color for r 2 superimposed. Figure 3 . Effect of the risk haplotype on UBE2L3 (a) mRNA and UBCH7 (b) protein expression. On the X axis, the three different genotypes for SNP rs7444 are displayed corresponding to homozygote of risk haplotype (C/C), heterozygote (C/T) and homozygote of non-risk haplotype (T/T). On the Y axis is the level of normalized expression for UBE2L3 for each assay. Each data point represents the expression level of UBE2L3 mRNA or UBCH7 protein for one individual.
and genetic data (Supplementary Table 3 ). The final data set, following QC exclusions, comprised 55 SNPs and 262 AIMs and 15 864 samples (Table 1) .
Association analyses
Single marker association analyses were calculated using the logistic regression function in PLINK v. 1.07 30 under the additive model adjusting for gender and global ancestry estimates (African, European and East Asian). Meta-analyses to combine P-values from different populations were performed using a weighted Z-score METAL. 31 We used both the Cochran's Q test statistic and I 2 index to test for heterogeneity in the meta-analysis. The Cochran's Q test calculates the weighted sum of the squared deviations between individual study effects and the overall effect across studies, 32 whereas the I 2 index measures the degree or percentage of inconsistency across studies due to heterogeneity rather than by chance. 33 LD between variants was estimated and probable haplotypes were calculated using Haploview 4.2, 34 followed by haplotypic association for all haplotypes formed by the associated markers across the various populations. Constructing haplotypes using all variants yielded the same haplotypes as the analysis using only the associated SNPs (results not shown).
Imputation
The IMPUTE2 software 35 Table 6 ) as reference genotypes. Imputation using the sequence data from our European-ancestry samples along with the 1000 Genome Project haplotypes was also performed. IMPUTE2 calculates posterior probabilities for the three possible genotypes (that is, AA, AB and BB). These probabilities were converted to the most possible genotypes with a threshold of 0.8. Imputed SNPs with the information measure o0.4 were excluded.
Resequencing, variant detection and QC
We resequenced 74 SLE cases and 100 controls of European ancestry and thereafter included the sequenced haplotypes into the genotype imputation. For each sample, 3 --5 mg of whole genomic DNA were sheared and prepared using an Illumina Paired-End Genomic DNA Sample Prep Kit. The SureSelect Target Enrichment System was used to enrich targeted regions of interest from each sample by utilizing a custom-designed bait pool. Resequencing was performed on an Illumina GAIIx platform using standard procedures with minimum average fold coverage of 25 Â . The Illumina Pipeline software v.1.7 was used to process post-sequence data.
Duplicate reads were excluded using a custom script, followed by alignment to the human reference genome build hg18 using the BWA alignment software version 0.5.9. 36 Realignment of reads around insertion/ deletion sites and problematic areas, base quality score recalibration and variation detection were processed using the Genome Analysis Tool Kit (GATK) software suite version 1.0. 37, 38 Variants clustered within 10 base pairs were filtered out, as well as any variant with a quality score o30, a quality by depth score less than 5, inclusion within a homopolymer run of 5 or more bases, or a strand bias score of 4À0.1. The program Beagle version 3.3 39 was utilized to determine variant phase. PLINK and IMPUTE2 format files were created using the vcftools software suite version 0.1.3. 40 To assess the quality of the sequence data, the sequence-based variant calls were compared with common SNPs previously genotyped with the Illumina iSelect platform. More than 99% concordance was observed suggesting high quality of our sequence data. Samples with more than 5% of variants inconsistent with genotype calls required a manual inspection of the assembled contig sequence to determine the sequence quality using the Integrative Genomics Viewer program. 41 The assembled contig sequence of each novel variant identified by our sequencing was also inspected using Integrative Genomics Viewer.
Cell culture RNA isolation and quantitative reverse transcription-PCR Total RNA was isolated using the Trizol total RNA isolation reagent (Invitrogen Inc., Carlsbad, CA, USA). The concentrations of total RNA were determined by using nanodrop, and were diluted with 20 ng ml À1 of MS2-RNA (Hoffmann-La Roche Inc., Nutley NJ, USA) to a final concentration of 0.5 mg ml À1 . Total RNA was treated with DNase and cDNA was synthesized using the iScript cDNA Synthesis Kits purchased from BioRad Laboratories Inc. (Hercules, CA, USA). Quantitative PCR was carried out using the SYBR Green method to determine the mRNA expression of UBE2L3. A pair of primers was designed and synthesized: sense, 
UBE2L3 protein expression
EBV-transformed B cells were harvested and lysed in whole-cell extraction buffer (25 mM Tris, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA and protease inhibitors). Concentrations of protein in each cell line were determined using Quick Start Bradford Protein Assay Kits and were adjusted to a final protein concentration of 2 mg ml À1 . Anti-UBE2L3 and anti-GAPDH antibodies were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA) and were used to detect protein expression of UBCH7 and GAPDH, respectively. ECL Plus Western Blotting Detection System was purchased from GE Heathcare Inc. (Amersham, UK). The intensity of each band was analyzed using the Image J (NIH) software. Protein expression of UBCH7 was normalized to GAPDH.
